Role of Aspirin in Breast Cancer Survival

Current Oncology Reports

Volumn 19, Issue 7, 2017, Pages

  Chen, Wendy Y ^a,b   Holmes, Michelle D ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aspirin; Breast cancer; COX 2; Inflammation; Survival

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; EVIDENCE BASED PRACTICE; GENERAL CONDITION IMPROVEMENT; HORMONAL REGULATION; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); NEOADJUVANT CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE CARE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; THROMBOCYTE COUNT; BREAST TUMOR; FEMALE; GENETICS; METASTASIS; PATHOLOGY; RISK FACTOR; SURVIVAL ANALYSIS;

ASPIRIN; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 85020638521     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-017-0605-6     Document Type: Review

References (78)

1. Elwood PC, et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One. 2016;11(4):e0152402.
2. • Huang XZ, et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control. 2015;26(4):589–600. This meta-analysis evaluates the association both including and excluding the randomized trial aspirin data
3. Zhong S, et al. Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies. Breast Cancer Res Treat. 2015;150(1):199–207.
4. Blair CK, et al. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat. 2007;101(2):191–7.
5. Fraser, D.M., et al., Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111(3):623–7.
6. Holmes, M.D., et al., Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467–72.
7. Holmes MD, et al. Aspirin intake and breast cancer survival—a nation-wide study using prospectively recorded data in Sweden. BMC Cancer. 2014;14:391.
8. Murray LJ, et al. Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res. 2014;16(2):R34.
9. Wernli KJ, et al. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf. 2011;20(2):131–7.
10. Barron TI, et al. Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. Cancer Res. 2014;74(15):4065–77.
11. Rothwell PM, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.
12. Falandry C, et al. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat. 2009;116(3):501–8.
13. Dirix LY, et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol. 2008;26(8):1253–9.
14. Dang CT, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 2004;10(12 Pt 1):4062–7.
15. Martin LA, et al. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res Treat. 2010;123(3):829–36.
16. Brandao RD, et al. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast cancer research: BCR. 2013;15(2):R29.
17. Aristarco V, et al. A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients. Cancer Prev Res (Phila). 2016;9(5):349–56.
18. Chow LW, et al. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol. 2008;111(1–2):13–7.
19. Goss PE, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31(11):1398–404.
20. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18(55):7908–16.
21. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006;6(2):130–40.
22. Bennett A, et al. Prostaglandins and breast cancer. Lancet. 1977;2(8039):624–6.
23. McFadden DW, et al. Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro. Int J Oncol. 2006;29(4):1019–23.
24. Liu W, et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol. 2003;26(4):S103–9.
25. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83(3):493–501.
26. Ristimaki A, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62(3):632–5.
27. Denkert C, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97(12):2978–87.
28. Wulfing P, et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol. 2003;129(7):375–82.
29. Baylin A, et al. Adipose tissue biomarkers of fatty acid intake. Am J Clin Nutr. 2002;76(4):750–7.
30. Costa C, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55(6):429–34.
31. Subbaramaiah K, et al. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem. 2002;277(21):18649–57.
32. Ranger GS, et al. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 2004;24(4):2349–51.
33. Spizzo G, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer. 2003;88(4):574–8.
34. Holmes MD, et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat. 2011;130(2):657–62.
35. • Hugo HJ, et al. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia. 2015;20(3–4):109–19. This article reviews potential mechanisms linking COX-2, inflammation, aspirin, and breast cancer
36. Zelenay S, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162(6):1257–70.
37. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996;56(22):5125–7.
38. Natarajan K, et al. Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression. Neoplasia. 2002;4(5):409–16.
39. Hwang D, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90(6):455–60.
40. Yoshimura N, et al. Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg Today. 2003;33(11):805–11.
41. Basu S, et al. Cellular expression of cyclooxygenase, aromatase, adipokines, inflammation and cell proliferation markers in breast cancer specimen. PLoS One. 2015;10(10):e0138443.
42. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–34.
43. Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost. 2007;33(7):712–21.
44. Mohle R, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94(2):663–8.
45. Coppinger JA, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103(6):2096–104.
46. Smyth SS, et al. Platelet functions beyond hemostasis. J Thromb Haemost. 2009;7(11):1759–66.
47. Holmes CE, et al. Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. Clin Transl Sci. 2013;6(5):386–90.
48. Sindelar WF, Tralka TS, Ketcham AS. Electron microscopic observations on formation of pulmonary metastases. J Surg Res. 1975;18(2):137–61.
49. Borsig L, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001;98(6):3352–7.
50. Nieswandt B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59(6):1295–300.
51. Felding-Habermann B, et al. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem. 1996;271(10):5892–900.
52. Elwood PC, et al. Aspirin, salicylates, and cancer. Lancet. 2009;373(9671):1301–9.
53. Rocca B, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002;99(11):7634–9.
54. Pulcinelli FM, et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol. 2004;43(6):979–84.
55. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62.
56. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261–74.
57. Franke TF, et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997;275(5300):665–8.
58. Banerji S, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405–9.
59. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res. 2010;16(15):3811–8.
60. Pandolfi PP. Breast cancer—loss of PTEN predicts resistance to treatment. N Engl J Med. 2004;351(22):2337–8.
61. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–19.
62. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008;27(41):5486–96.
63. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
64. Glynn SA, et al. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer. 2010;10:626.
65. Liao X, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–606.
66. • Domingo E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31(34):4297–305. This is one of several studies that show that the aspirin association for colorectal cancer is more strongly seen with PI3K mutant tumors
67. Din FV, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142(7):1504–15. e3
68. Hudson AG, et al. Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomark Prev. 2008;17(3):680–7.
69. Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.
70. Duggan, C., et al., Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial. Cancer Prev Res. 2014;7(9):906–912.
71. Fortner RT, et al. Analgesic use and patterns of estrogen metabolism in premenopausal women. Horm Cancer. 2014;5(2):104–12.
72. Burstein HJ, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.
73. Brodie AM, et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol. 2001;79(1–5):41–7.
74. Brueggemeier RW, et al. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol. 2005;95(1–5):129–36.
75. Karuppu D, et al. Aromatase and prostaglandin inter-relationships in breast adipose tissue: significance for breast cancer development. Breast Cancer Res Treat. 2002;76(2):103–9.
76. Subbaramaiah K, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2012;2(4):356–65.
77. • Bowers LW, et al. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions. Cancer Res. 2014;74(16):4446–57. This study combines both epidemiologic and in vitro data to evaluate how NSAID use may decrease breast cancer recurrence
78. Morris PG, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res. 2011;4(7):1021–9.